Core Viewpoint - The company is selling a 51% stake in Fujian Jianchen Pharmaceutical Co., Ltd. for RMB 1.6779 million due to declining performance and high fixed costs associated with its operations [1] Group 1: Company Actions - The company’s wholly-owned subsidiary, Zhejiang Health Road Technology Group Co., Ltd., is the entity involved in the sale [1] - The decision to sell the stake is driven by the need to reduce costs and improve efficiency amid disappointing financial performance [1] Group 2: Financial Performance - The company experienced a temporary revenue increase due to stockpiling of Oseltamivir during the flu outbreak at the end of 2023 [1] - Following the decline of the pandemic, the limitations of being a single-product pharmaceutical wholesaler became apparent, leading to a significant drop in revenue and net profit starting August 2024 [1] - Fixed costs related to drug procurement, storage, transportation, and employee salaries are relatively high, contributing to the decision to divest [1] Group 3: Future Plans - Proceeds from the sale will be used to develop the company’s enterprise services and digital marketing services [1]
健康之路附属拟出售福建健宸医药有限公司51%的股权